Compare IDXX & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | ZTS |
|---|---|---|
| Founded | 1983 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5B | 53.9B |
| IPO Year | 1991 | 2013 |
| Metric | IDXX | ZTS |
|---|---|---|
| Price | $689.02 | $126.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $700.50 | $174.60 |
| AVG Volume (30 Days) | 536.9K | ★ 6.1M |
| Earning Date | 02-02-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | ★ 21.65 | 11.64 |
| EPS | ★ 12.60 | 5.94 |
| Revenue | $4,167,411,000.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $12.15 | $3.04 |
| Revenue Next Year | $8.72 | $4.98 |
| P/E Ratio | $54.61 | ★ $21.14 |
| Revenue Growth | ★ 8.39 | 2.68 |
| 52 Week Low | $356.14 | $115.25 |
| 52 Week High | $769.98 | $177.40 |
| Indicator | IDXX | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 57.01 |
| Support Level | $676.06 | $121.12 |
| Resistance Level | $711.68 | $125.53 |
| Average True Range (ATR) | 15.70 | 2.71 |
| MACD | -3.86 | 1.15 |
| Stochastic Oscillator | 27.11 | 99.67 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.